UroGen Pharma is trading at $36.27, down 10.88%, amid healthcare-sector weakness and broader risk-off concerns.
- No new company-specific announcement surfaced; the UGN-103 discussion was from a September conference, not an October 8 catalyst.
- Riyadh attacks and a surge in oil prices heightened inflation and risk-off concerns.
- Healthcare was down 1.49%; broader indexes were mixed-to-lower. These are market and sector context, not proof of the full decline’s cause. No volume data was provided.